Apellis Pharmaceuticals Inc (APLS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2023 | 06-2023 | 03-2023 | 12-2022 | 09-2022 | |
| Sales | 110,399 | 94,969 | 44,846 | 22,663 | 22,056 |
| Cost of Goods | 22,410 | 8,379 | 7,809 | 2,926 | 1,381 |
| Gross Profit | 87,989 | 86,590 | 37,037 | 19,737 | 20,675 |
| Operating Expenses | 225,479 | 207,410 | 212,929 | 184,716 | 173,994 |
| Operating Income | -137,080 | -120,441 | -175,083 | -164,053 | -152,938 |
| Interest Expense | 7,310 | 7,341 | 7,529 | 7,737 | 7,903 |
| Other Income | 4,386 | 5,939 | 5,116 | 4,328 | -29,982 |
| Pre-tax Income | -140,004 | -121,843 | -177,496 | -167,462 | -190,823 |
| Income Tax | 233 | 194 | 282 | -1,471 | 446 |
| Net Income Continuous | -140,237 | -122,037 | -177,778 | -165,991 | -191,269 |
| Net Income | $-140,237 | $-122,037 | $-177,778 | $-165,991 | $-191,269 |
| EPS Basic Total Ops | -1.17 | -1.02 | -1.56 | -1.52 | -1.75 |
| EPS Basic Continuous Ops | -1.17 | -1.02 | -1.56 | -1.51 | -1.75 |
| EPS Diluted Total Ops | -1.17 | -1.02 | -1.56 | -1.52 | -1.75 |
| EPS Diluted Continuous Ops | -1.17 | -1.02 | -1.56 | -1.51 | -1.75 |
| EBITDA(a) | $-130,130 | $-113,497 | $-167,956 | $-136,570 | $-165,821 |